Shares of Endo International PLC (NASDAQ:ENDP) shot up 1.1% during mid-day trading on Tuesday . The stock traded as high as $17.25 and last traded at $17.06, with a volume of 3,602,319 shares changing hands. The stock had previously closed at $16.88.

Several brokerages have recently issued reports on ENDP. Barclays PLC restated a “hold” rating on shares of Endo International PLC in a research report on Sunday, May 8th. JMP Securities restated a “buy” rating and set a $52.00 target price (down from $56.00) on shares of Endo International PLC in a research report on Sunday, May 8th. Mizuho cut shares of Endo International PLC from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $42.00 to $13.00 in a research report on Tuesday, May 3rd. Zacks Investment Research cut shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Finally, Stifel Nicolaus decreased their target price on shares of Endo International PLC from $90.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $39.19.

The stock’s 50-day moving average price is $16.84 and its 200-day moving average price is $29.72. The firm’s market cap is $3.81 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.04. The firm earned $963.54 million during the quarter, compared to analysts’ expectations of $960.96 million. The company’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.17 earnings per share. Analysts predict that Endo International PLC will post $4.55 EPS for the current year.

In related news, Director Arthur J. Higgins bought 5,000 shares of the stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average price of $13.80 per share, for a total transaction of $69,000.00. Following the acquisition, the director now owns 50,623 shares in the company, valued at approximately $698,597.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Arthur J. Higgins bought 11,000 shares of the stock in a transaction dated Tuesday, May 10th. The stock was bought at an average price of $15.42 per share, with a total value of $169,620.00. Following the acquisition, the director now owns 45,623 shares in the company, valued at approximately $703,506.66. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors recently modified their holdings of the company. Cibc World Markets Corp bought a new position in shares of Endo International PLC during the fourth quarter valued at about $47,081,000. RS Investment Management Co. LLC boosted its position in shares of Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock valued at $33,279,000 after buying an additional 123,692 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares during the last quarter. Finally, Advantus Capital Management Inc boosted its position in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock valued at $1,223,000 after buying an additional 476 shares during the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.